New diagnostic criteria for multiple sclerosis integrating magnetic resonance image
assessment with clinical and other paraclinical methods were introduced in 2001. The “McDonald …

… Polman has received compensation for activities from Actelion, Biogen Idec, Glaxo Smith
Kline, Merck Serono, MorphoSys AG, Novartis, Receptos, and Teva as consultant/committee …

We compared MRI criteria used to predict conversion of suspected multiple sclerosis to
clinically definite multiple sclerosis. Seventy-four patients with clinically isolated neurological …

Background Natalizumab is the first α 4 integrin antagonist in a new class of selective
adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in …

New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis
of multiple sclerosis. The use of imaging for demonstration of dissemination of central …

The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple
sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in …

Background Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation
for the treatment of relapsing multiple sclerosis. Methods We randomly assigned 281 …

Objective: To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b
treatment in patients with a first clinical event suggestive of multiple sclerosis (MS) (clinically …

There is evidence that treatment with an antibody to tumor necrosis factor alpha (TNF alpha)
improves an animal model of multiple sclerosis (MS) and is beneficial in two systemic …

Magnetic resonance imaging (MRI) monitoring of disease progression in multiple sclerosis
is limited by the lack of correlation of abnormalities seen on T2‐weighted imaging, and …